Novartis News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

03.12.07	FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children (PR Newswire)
13.11.07	Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers (PR Newswire)
22.10.07	Exelon(R) (rivastigmine) Transdermal Patch: First and Only Skin Patch for Alzheimer's Disease Provides Novel Treatment Approach (PR Newswire)
22.10.07	Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis (PR Newswire)
22.10.07	Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis (PR Newswire)
18.09.07	First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival (PR Newswire)
15.06.07	Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension (PR Newswire)
17.04.07	Reclast(R) Receives US Approval as a Highly Effective Treatment for Patients with Paget's Disease of the Bone (PR Newswire)
26.03.07	Tekturna(R), First New Type of High Blood Pressure Medicine in a Decade, Provides Additional Blood Pressure Reduction When Used With Diovan(R) (PR Newswire)
06.12.06	New Evidence Reinforces Efficacy and Tolerability of Galvus(R) as a New Once-Daily Oral Treatment Option for Patients With Type 2 Diabetes (PR Newswire)
27.10.06	New Telbivudine Data From Three Clinical Trials to be Presented This Week at the American Association for the Study of Liver Diseases (AASLD) (PR Newswire)
26.10.06	New BOOST(R) Glucose Control(TM) Helps Provide Optimal Blood Sugar Control for People with Diabetes (Businesswire)
18.10.06	AUDIO from Medialink: Visions of Halloween Fun (Businesswire)
17.10.06	Celebrity Photographer Jeremy Kost Creates Images of Isolation to Empower Eczema Patients to Share Their Stories and Take Control (PR Newswire)
05.10.06	New Treatment Significantly Improves Vision in Patients With Wet Age-Related Macular Degeneration - The Leading Cause of Blindness in the UK (PR Newswire)
04.10.06	Millions Live with Painful GI Symptoms Impacting Their Lives, but Sufferers Rarely Discuss Symptoms with Doctors Due to Fear and Embarrassment (PR Newswire)
28.09.06	New Data for FTY720 -- Aiming to Become the First Orally Effective Multiple Sclerosis Treatment -- Show Sustained Benefits Over Two Years (PR Newswire)
21.09.06	No More Needles - a New Breakthrough for Iron Overload (PR Newswire)
21.09.06	No More Needles - A New Breakthrough for Iron Overload (PR Newswire)
29.08.06	Tennis Mom Betty Agassi Shares Her Battle With Breast Cancer and Champions Disease Awareness at the US Open (PR Newswire)
14.08.06	Schering-Plough Announces Global Agreement With Novartis to Develop Once-Daily Combination Therapy for Asthma and COPD (PR Newswire)
11.08.06	Women With Breast Cancer No Longer Have to Settle for Second Class Treatments (PR Newswire)
25.07.06	From Touchdowns to Touching Lives: Football Superstar Tiki Barber Aims to Make a 'Giant' Difference for Children and Their Families Coping With Sickle Cell Disease (PR Newswire)
24.07.06	Study Shows Neoral(R) Provides Kidney Transplant Patients With Efficacy Equivalent to Tacrolimus and Significantly Lower Incidence of Diabetes (PR Newswire)
18.07.06	Novartis to Build Latest-Technology Influenza Vaccines Manufacturing Site in North Carolina (PR Newswire)
14.06.06	Patients With Treatment-Resistant Leukemia Achieve High Responses to Tasigna(R) (nilotinib) in First Published Clinical Trial Results (PR Newswire)
13.06.06	Novartis Unveils Further Impressive Efficacy Data for Galvus(R), an Investigational Oral Diabetes Compound, Showing Significant Blood Sugar Reductions (PR Newswire)
24.05.06	The First and Only Medicine for Parkinson's Disease Dementia is Now Available (PR Newswire)
23.05.06	New Data Show Overactive Bladder Therapy Enablex(R) Does Not Impair Memory Function Compared to Frequently Used Alternative (PR Newswire)
23.05.06	NICE Initial Recommendation: One Step Closer to Backing Aromatase Inhibitor Treatment for Women With Early Breast Cancer (PR Newswire)
22.05.06	Study Reveals Zelnorm(R) May Be a Safe and Effective Treatment for Additional Group of IBS Patients With a Mixed Bowel Pattern (PR Newswire)
19.05.06	Diovan(R) (valsartan) the First Blood Pressure Medication in a Large-Scale Clinical Trial to Lower C-Reactive Protein, an Important Marker of Inflammation (PR Newswire)
17.05.06	FDA Advisory Committee Recommends Approval of Exelon(R) (rivastigmine tartrate) in the Treatment of Dementia Associated with Parkinson's Disease (PR Newswire)
08.05.06	Scottish Women are the First to be Given More Hope in the Fight Against Early Breast Cancer (PR Newswire)
28.04.06	MZ Announces Conclusion of Latin American Company Reports Related to the 2006 Investor Relations Global Rankings (IRGR) and Awards (PR Newswire)
24.04.06	Seven Summits Research Releases Comments on AXP, AMTD, SLAB, WEN, and NVS (PR Newswire)
30.03.06	New drug application for Galvus(R), an innovative oral therapy for people with type 2 diabetes, accepted for review by FDA (PR Newswire)
29.03.06	Idenix gibt bekannt, dass Novartis Valopicitabin (NM283) in Lizenz nimmt (PR Newswire)
23.03.06	New Clinical Data Show Benefits of Femara(R) for Women With Breast Cancer Even After Prolonged Period of no Anti-Cancer Treatment Post tamoxifen (PR Newswire)
16.03.06	Conor Medsystems Licenses Pimecrolimus From Novartis for Use in Next-Generation Reservoir-Based Drug-Eluting Stents (PR Newswire)
03.03.06	Single-Dose Famvir(R) Treatment Found To Accelerate Healing Time of Cold Sore Outbreaks (PR Newswire)
18.01.06	Novartis Accelerates Production of Life-Saving Malaria Treatment Coartem(R) (PR Newswire)
28.12.05	Femara(R) Receives US Approval as Initial Therapy for Postmenopausal Women With Early Breast Cancer After Surgery (PR Newswire)
18.12.05	Single-Day Famvir Treatment Found to Shorten the Duration of Recurrent Genital Herpes Outbreaks (PR Newswire)
13.12.05	New Clinical Data Show Dramatic Benefits of Femara(R) for Women with Breast Cancer Even After Prolonged Period of No Anti-Cancer Treatment (PR Newswire)
13.09.05	Survey Finds 43 Percent of Americans Suffer with Common GI Disorders (PR Newswire)
14.07.05	Three Real Women Offer Insight Into Their Hysterectomy Surgeries in New Documentary (PR Newswire)
27.05.05	FDA Grants Approval to Market Focalin XR(TM) for the Treatment of ADHD in Adults, Adolescents and Children (PR Newswire)
15.05.05	New Data Show Zometa(R) Significantly Improved Bone Mineral Density in Breast Cancer Patients Receiving Adjuvant Therapy (PR Newswire)
03.05.05	Novartis Files Exjade(R) New Drug Applications for Treatment of Chroni (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	71.14	1.54 %	K V
UBS Group	28.08	1.48 %	K V
Swiss Re	130.05	1.05 %	K V
Part Grp Hldg	1’266.00	0.96 %	K V
ABB	49.48	0.94 %	K V
Geberit	525.20	0.27 %	K V
Alcon	78.04	0.05 %	K V
Givaudan	3’868.00	-0.31 %	K V
CieFinRichemont	121.20	-0.57 %	K V
Sonova Hldg	301.00	-0.99 %	K V

mehr

12.07.24		Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an
12.03.24		MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis
31.01.24		Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung
12.06.23		Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch
25.04.23		Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an
07.12.22		MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert
19.07.22		Novartis-Aktie höher: Novartis bei nahezu stabilen Umsätzen mit Gewinnrückgang - Umbau soll 1,5 Milliarden US-Dollar Kosten sparen
06.05.22		Novartis-Aktie im Minus: Produktion von Krebsmitteln in Italien und USA ausgesetzt